Moderna, Inc. Increase (Decrease) in Accounts Receivable, Related Parties
Moderna, Inc. (MRNA) reported Increase (Decrease) in Accounts Receivable, Related Parties of $1.35 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties · last filed 2020-05-07
- Moderna, Inc. increase (decrease) in accounts receivable, related parties for the quarter ending 2020-03-31 was $1.35M, a 1939.39% increase year-over-year.
- Moderna, Inc. increase (decrease) in accounts receivable, related parties for the quarter ending 2019-12-31 was -$5.08M.
- Moderna, Inc. increase (decrease) in accounts receivable, related parties for the quarter ending 2019-09-30 was $4.40M, a 366.67% increase year-over-year.
- Moderna, Inc. increase (decrease) in accounts receivable, related parties for the quarter ending 2019-06-30 was $55.00K.
- Moderna, Inc. increase (decrease) in accounts receivable, related parties for fiscal 2019 was -$562.00K.
- Moderna, Inc. increase (decrease) in accounts receivable, related parties for fiscal 2018 was -$637.00K, a 146.50% decline from fiscal 2017.
- Moderna, Inc. increase (decrease) in accounts receivable, related parties for fiscal 2017 was $1.37M.
- Moderna, Inc. increase (decrease) in accounts receivable, related parties for fiscal 2016 was -$60.98M.
| Period end | Increase (Decrease) in Accounts Receivable, Related Parties 3 month | Increase (Decrease) in Accounts Receivable, Related Parties 6 month | Increase (Decrease) in Accounts Receivable, Related Parties 9 month | Increase (Decrease) in Accounts Receivable, Related Parties 12 month |
|---|---|---|---|---|
| 2020-03-31 | $1.35M 10-Q · filed 2020-05-07 | -$3.73M derived: sum of 2 quarters · filed 2020-05-07 | $663.00K derived: sum of 3 quarters · filed 2020-05-07 | $718.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | -$5.08M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$683.00K derived: sum of 2 quarters · filed 2020-02-27 | -$628.00K derived: sum of 3 quarters · filed 2020-02-27 | -$562.00K 10-K · filed 2020-02-27 |
| 2019-09-30 | $4.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $4.45M derived: sum of 2 quarters · filed 2019-11-06 | $4.52M 10-Q · filed 2019-11-06 | $3.70M derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-06-30 | $55.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $121.00K 10-Q · filed 2019-08-08 | -$692.00K derived: sum of 3 quarters · filed 2020-05-07 | $250.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-03-31 | $66.00K 10-Q · filed 2020-05-07 | -$747.00K derived: sum of 2 quarters · filed 2020-05-07 | $195.00K derived: sum of 3 quarters · filed 2020-05-07 | -$29.10M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$813.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $129.00K derived: sum of 2 quarters · filed 2020-02-27 | -$29.17M derived: sum of 3 quarters · filed 2020-02-27 | -$637.00K 10-K · filed 2020-02-27 |
| 2018-09-30 | $942.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$28.35M derived: sum of 2 quarters · filed 2019-11-06 | $176.00K 10-Q · filed 2019-11-06 | |
| 2018-06-30 | -$29.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$766.00K 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $28.53M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $1.37M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | -$60.98M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |